ESBL- From Petri dish to the patient

Indian Journal of Medical Microbiology

Volumn 24, Issue 1, 2006, Pages 20-24

  Bhattacharya, S ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ESBL; Non antibiotic approach; OPAT; Pharmaco therapy; Screening

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CREATININE; CYCLOSPORIN; ERTAPENEM; ESTROGEN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MECILLINAM; MEROPENEM; NITROFURANTOIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM;

ABSCESS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BRAIN ABSCESS; COLITIS; CREATININE CLEARANCE; DECISION MAKING; DIARRHEA; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; ENDOCARDITIS; ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; INDIA; MEDICAL LITERATURE; MENINGITIS; NEPHROTOXICITY; NEWBORN HEMOLYTIC DISEASE; OTOTOXICITY; OUTPATIENT CARE; PNEUMONIA; PROSTHESIS INFECTION; REVIEW; SEIZURE; SEPSIS; TERATOGENICITY; URINARY TRACT INFECTION;

EID: 33645500264     PISSN: 02550857     EISSN: 02550857     Source Type: Journal    
DOI: 10.4103/0255-0857.19889     Document Type: Review

References (15)

1. Chaudhury U, Aggarwal R. Extended spectrum beta-lactamases (ESBL)- An emerging threat to clinical therapeutics. Indian J Med Microbiol 2004;22:75-80.
2. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-94.
3. Bradford PA. Extended-Spectrum -Lactamases in the 21st Century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
4. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004;350:1422-9.
5. Iannini PB. Hospital-acquired Urinary Tract Infections: Implications for Treatment and Prevention. Curr Tr Op Infect Dis 2002;4:15-20.
6. Pattharachayakul S, Neuhauser MM, Quinn JP, Pendland SL. Extended-spectrum beta-lactamase (ESBE)-producing Klebsiella pneumoniae:activity of single versus combination agents. J Antimicrob Chemother 2003;51:737-9.
7. Paterson DL. B-Lactamase inhibitors and new beta -lactamases. Curr Treat Opt Infect Dis 1999;1:85-87.
8. Lutters M, Vogt N. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd; 2004. http:// www.cochrane.org/cochrane/revabstr/ab001535.htm
9. Bloomfield P, Hodson EM, Craig JC. Antibiotics for acute pyelonephritis in children (Cochrane Review). In:The Cochrane Library, Issue 3. Chichester, UK:John Wiley & Sons, Ltd; 2004. http://www.cochrane.org/cochrane/revabstr/ ab003772.htm
10. Electronic Medicines Compendium. www.medicines.org.uk
11. British National Formulary. http://www.bnf.org/bnf/
12. Tice AD. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. J Antimicrob Chemother 2004;53:83-6.
13. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum -Lactamases: Implications for the Clinical Microbiology Laboratory. J Clin Microbiol 2001;39:2206-12.
14. Mathai D, Rhomberg PR, Biedenbach DJ, Jones RN. India Antimicrobial Resistance Study Group. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn Microbiol Infect Dis 2002;44:367-77.
15. Fergusson J. On behalf of the AICA National Advisory Board. Aust Infect Con 2002;7;http://www.aica.org.au/docs/about/ downloads/definition2.pdf